news
RN7SL1 RNA shown to activate T cells to fight against cancer
A new study found that the RNA RN7SL1 can activate T cells to seek out cancer cells, potentially improving cellular treatments.
List view / Grid view
Chimeric antigen receptors (CARs)
news
CAR T cells targeting the CEACAM7 protein show promise in pancreatic cancer
CAR T cells modified to recognise CEACAM7 were able to eliminate pancreatic ductal adenocarcinoma cells in a late-stage model without toxic effects on healthy tissue.
news
Could synNotch CAR T cells be the answer to fighting solid tumours?
Researchers have developed a novel CAR T-cell therapy for neuroblastoma which uses gating to limit toxicity and T-cell exhaustion.
article
A novel CAR T-cell therapy to treat lymphomas
A new form of CAR T-cell therapy has shown promise in mice models to treat blood cancers; this article delves into the development behind the therapy.
news
Activating STING enhances CAR T-cell activity in solid tumours, shows study
Researchers were able to eradicate breast cancer in mice when they combined CAR T cells with STING pathway agonists and immunotherapeutic antibodies.
news
A novel CAR T-cell therapy for type 1 diabetes
Researchers show how genetically engineered five-module chimeric antigen receptor (5MCAR) T cells can be directed to destroy T cells causing autoimmune diseases.
news
Novel CAR T-cell therapy could help cure HIV
The designers of the Dual Chimeric Antigen Receptor (CAR) T cell therapy report it slows HIV replication and leads to a smaller viral reservoir in HIV-infected mice.
news
Experimental CAR T therapy targets solid tumour cancer cells
Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
article
Using big data approaches to develop cell therapies
An area where stem cell biology and medicine are combining effectively is the establishment of new cell therapies. However, current therapies are limited to a narrow set of cell types that can be isolated or created and expanded in vitro. Dr Owen Rackham discusses how utilising computational approaches will further…
article
Triplet immuno-oncology drug combinations – the future of treating multiple cancer
The oncology market is saturated with new drugs that target the immune system, however, these only target part of the problem caused by cancer’s ability to hide from the immune system. Miguel Ferreira discusses why emerging three-drug combinations are poised to redefine the immuno-oncology treatment paradigm in advanced malignancies with…
news
Could T-cell immunotherapy be the answer to COVID-19?
Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
news
Researchers develop CAR-T therapy that targets multiple leukaemia sites
A new CAR T-cell therapy has been created by researchers which targets three proteins on leukaemia cells and has shown success in pre-clinical trials.
news
Novel CAR T-cell immunotherapy eradicates solid tumours in mice
Researchers have developed a new CAR T-cell therapy that targets an antigen called glycipan-1 (GPC1), showing efficacy at fighting solid tumours in mice.
article
TCR therapy – an attractive alternative to CAR T
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
news
Using blue light to control CAR T cells and destroy tumours
Researchers have created a method to activate CAR T cells with blue LED light to successfully combat solid tumours in mice.
